Bavarian Nordic Increases Share Capital by DKK 285,900

COPENHAGEN, Denmark, September 4, 2026 /CourierPR/ -- Bavarian Nordic A/S has announced a recent increase in its share capital, reflecting the exercise of employee warrants. The company’s share capital has grown by DKK 285,900, with 28,590 new shares being issued at a price of DKK 190.11 per share. This capital increase, which took place without any pre-emption rights for existing shareholders, brought in a total of DKK 5.4 million for the company.

These newly issued shares will be identical in all respects to the existing shares and will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible. The total nominal value of Bavarian Nordic A/S' share capital now stands at DKK 792,653,180, comprising 79,265,318 shares of DKK 10 each, which corresponds to 79,265,318 votes.

The revised Articles of Association will be published shortly on the company's website, reflecting the changes resulting from the capital increase.

Bavarian Nordic, a global vaccine company with a mission to improve health and save lives through innovative vaccines, continues its efforts to enhance public health preparedness. The company is a key supplier of mpox and smallpox vaccines to governments around the world, in addition to maintaining a leading portfolio of travel vaccines.

This capital increase is part of the ongoing operations and financial health of the company. Bavarian Nordic remains committed to its mission and to providing essential vaccines that contribute to global health security.